Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers by Khan, AA et al.
Association between pretreatment haemoglobin levels and
morphometric characteristics of the tumour, response to
neoadjuvant treatment and long-term outcomes in patients
with locally advanced rectal cancers
A. A. Khan*, M. Klonizakis†, A. Shabaan‡ and R. Glynne-Jones*
*Department of Gastrointestinal Research, Mount Vernon Cancer Treatment and Research Centre, London, UK, †Faculty of Health and Wellbeing,
Centre for Sports and Exercise Science, Shefﬁeld Hallam University, Shefﬁeld, UK and ‡Department of Clinical Oncology, Minia University Hospital,
Al-Minia, Egypt
Received 17 October 2012; accepted 23 January 2013; Accepted Article online 25 May 2013
Abstract
Aim The study was carried out to investigate whether
pretreatment haemoglobin (Hb) levels act as a biomar-
ker in the management of patients with locally advanced
rectal cancer.
Method We prospectively collected data on all patients
within our cancer network with localized low rectal
cancer treated with preoperative radiotherapy/chemora-
diotherapy at Mount Vernon Centre for Cancer Treat-
ment between March 1994 and July 2008. Pretreatment
Hb level was assessed as an independent variable for the
whole study sample and dichotomised at a value of 12 g/dl.
A multivariate analysis of covariance (MANCOVA) was
conducted on parameters that had signiﬁcant association
on univariate analysis of covariance (ANCOVA) and cor-
relational (Kendall tau/Pearson) analyses. Kaplan–Meier
survival analysis and Cox proportional hazard models
were used to determine signiﬁcant prognostic markers.
Statistical signiﬁcance was set at 0.05.
Results 463 patients (male/female 2:1; median age =
66 years, interquartile range = 56.5–73.0) were included
in the analysis. There was signiﬁcant tumour response of
T stage (P < 0.001) and N stage (P < 0.001), with
17.6% of patients achieving a pathological complete
response. Pretreatment Hb value was inversely related to
the craniocaudal vertical tumour length (P = 0.02) and
pretreatment T stage of the tumour (P = 0.01). Patients
with Hb levels of < 12 g/dl and moderately differenti-
ated adenocarcinoma were less responsive. Local recur-
rence was more common in patients with a pretreatment
Hb of < 12 g/dl (hazard ratio = 1.78) over a median
follow up of 24 months, but this was not statistically
signiﬁcant (P = 0.08).
Conclusion The pretreatment Hb level might be used
as a biomarker of rectal tumour morphology, response
to neoadjuvant chemoradiation and risk of local recur-
rence.
Keywords Rectal carcinoma, neoadjuvant, radiother-
apy, chemoradiation, haemoglobin
What does this paper add to the literature?
Pretreatment Hb level may distinguish rectal cancer
subtypes and could contribute to management.
Introduction
Locally advanced rectal cancer (LARC) has a high risk of
local recurrence and distant metastases. The ability to
identify patients at a higher risk of local failure using clini-
cal, genetic and histopathogical biomarkers might allow
individualized treatment and offer more effective and less-
toxic treatments. However, biomarkers and tumour
response to treatment have rarely been tested prospectively
in large randomized studies and have not entered everyday
clinical practice [1].
The presence of anaemia at the time of diagnosis, or
its development during the course of neoadjuvant treat-
ment, has been shown to be of prognostic value in
patients with curable rectal cancer [2–5]. Anaemia is a
common presenting feature of patients with colorectal
cancers [6] and may be associated with a more aggres-
sive tumour behaviour and radioresistance [7]. The ‘low
oxygen tension’ within the tumour bed promotes
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lines that are capable of surviving at low levels of oxy-
gen [8]. In addition, chemoradiotherapy is also less
effective because the cytotoxic effect of ionizing radia-
tion and some chemotherapeutics are dependent on the
formation of oxygen radicals [9].
The presence of anaemia in patients with newly diag-
nosed rectal cancer may indicate a larger tumour with
advanced disease or an inherent feature of biologically
aggressive behaviour. The haemoglobin (Hb) level at
diagnosis may provide insight into rectal tumour mor-
phology and biology. To our knowledge, this hypothe-
sis has not been previously tested.
The aim of the present study was to investigate
whether Hb levels at diagnosis can be used (i) as a bio-
marker of rectal tumour morphology and hence reﬂect
the stage of disease, (ii) to predict rectal cancer response
to neoadjuvant treatment, and (iii) to determine long-
term cancer speciﬁc outcome.
Method
Patients
We analysed data on all consecutive patients from our
prospectively collected database. All patients had histo-
logically proven adenocarcinoma of the rectum and were
planned for curative treatment with neoadjuvant radio-
therapy, with or without concomitant chemotherapy, at
the Mount Vernon Cancer Treatment and Research
Centre between March 1994 and December 2008. The
data collected are presented in Tables 1 and 2.
Deﬁnition of parameters
We conducted the analysis using ‘Hb level’ as a contin-
uous variable and dichotomised the study population
for further analysis at the Hb value of 12 g/dl. This
Hb level cut-off value was based on the ﬁndings of Vau-
pel [8,10] who showed that Hb levels of < 12 g/dl
result in signiﬁcant tumour hypoxia, thus altering its
behaviour. The same cut-off value has been used to
deﬁne anaemia in previous studies on this topic [2].
‘Tumour morphology’ was deﬁned by pretreatment
endoluminal tumour length, circumferential nature, dis-
tance from the anal verge, differentiation and T stage
and pathophysiological attributes such as lymph node
involvement, distant spread and carcinoembryonic
antigen (CEA) levels. The ‘nRT regime’ was either
short-course (SCPRT: 20 Gy in ﬁve daily fractions) or
long-course (LCRT: 45 Gy in 25 fractions over 5 weeks),
either alone or with ﬂuoropyrimidine-based regime, with
a few patients receiving additional cytotoxic drugs
Table 1 Data collected and descriptive statistics.
Characteristic Value
Gender, n (%)
Female 149 (32.2)
Male 314 (67.8)
Age (years)
Median 66
IQR 56.5–73.0
ASA grading, n (%)
1 28 (12.6)
2 141 (63.2)
3 53 (23.8)
4 1 (0.4)
Haemoglobin level (g/dl)
Mean 12.96
SD 1.8
Range 8.2–19.5
CEA level (μg/l)
Median 4
IQR 2–10
Tumour characteristics, n (%)
Primary 443 (96.1)
Recurrent 18 (3.9)
Distance from anal verge (cm)
Mean 5.07
SD 2.7
Range 0–18
Tumour length (cm)
Mean 5.78
SD 2.2
Range 0–14
Tumour staging, n (%)
T2 26 (6.1)
T3 219 (51.5)
T4 180 (42.4)
N0 147 (35.0)
N1 156 (37.1)
N2 116 (27.6)
N3 1 (0.2)
M0 381 (93.8)
M1 25 (6.2)
Type of operation, n (%)
Anterior resection 154 (33.3)
APER 232 (49.9)
Hartmann’s 4 (0.9)
Not resectable 65 (14.0)
Refused surgery 8 (1.7)
Postoperative complications, n (%)
No 248 (63.3)
Yes 144 (36.7)
APER, abdominoperineal excision of the rectum; ASA, Ameri-
can Society of Anesthesiology; IQR, interquartile range.
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in the analysis for local recurrence. ‘Downstaging’ was
deﬁned by comparing the most advanced radiological
stage (cTNM) with the histological stage (ypTNM).
Consultant colorectal surgeons claimed to undertake
standard ‘total mesorectal excision (TME) surgery’, but
we have no data on the quality of the mesorectal excision
[11]. ‘Pathological complete response’ was deﬁned as no
evidence of malignant cells on microscopic examination
(although no standardized procedure was performed
[12]. Patients were followed for a median of 24 months
and 230 for at least 21 months.
Statistical analysis
For the purpose of this report, univariate and multivari-
ate analyses were carried out for the entire population
and populations in each Hb group. Failures for the efﬁ-
cacy end-points were as follows: overall survival: death
from any cause; and disease-free survival: locoregional
failure, distant failure or death from any cause. All end-
points were assessed from the start of treatment to the
date of ﬁrst failure for the given end-point or the date
of the last follow up for patients who did not fail at a
given end-point.
Initial statistical analysis explored baseline correla-
tions between independent variables from the data set
(Table 1) and study end-points using Kendall’s tau and
Pearson tests. The strength of any correlation was fur-
ther examined by univariate analysis of covariance
(ANCOVA) followed by multivariate analysis of covari-
ance (MANCOVA). The Wilcoxon signed-rank test was
used to assess tumour down-staging. Survival analyses
were performed using the Kaplan–Meier method and
comparisons were tested using the log-rank test. Back-
ward stepwise (likelihood ratio) Cox-regression survival
analysis was used to establish a model displaying any
relationships between chosen variables and outcomes.
Statistical signiﬁcance was set at P < 0.05. The data
were analysed using SPSS 19 (IBM, USA).
Results
Descriptive results
A total of 463 patients (male/female ratio = 2:1; median
age = 66 years; interquartile range (IQR) = 56.5–73.0)
were included in the analysis (Table 1). Twenty-seven
(0.05%) patients received SCPRT only and the remain-
der received LCRT with concomitant chemotherapy. In
the LCRT group, the median interval to surgery was 69
(IQR = 55–83) days. There was signiﬁcant tumour
response of T stage [number of patients who responded
(mean rank) = 170 (94.25); number of patients with
progression (mean rank) = 12 (52.2); P < 0.001] and N
stage [number of patients who responded (mean
rank) = 140 (88.43); number of patients with progres-
sion (mean rank) = 32 (78.08); P < 0.001] regression,
with 17.6% of patients achieving a pathological complete
response. In 65 (14%) patients the tumour was unresec-
table, and eight (1.7%) patients refused surgery.
Hb vs morphometric tumour characteristics
The pretreatment Hb level had a signiﬁcant, inverse
relationship with tumour length (univariate P = 0.002;
multivariate P = 0.02) and pretreatment clinical T stage
(P = 0.01). There was no association between Hb levels
and clinical N stage (P = 0.8), distance from the anal
verge (P = 0.68) and baseline CEA values (P = 0.8).
Hb vs response to neoadjuvant treatment
As a continuous variable, the pretreatment Hb level
did not show any association with tumour response;
Table 2 Different neoadjuvant chemotherapy regimes for the
study group.
Chemotherapy regime Number of patients
No chemotherapy 54
5-FU 3
5-FU (BOSSET regime) 189
5-FU + folinic acid 18
5-FU + leucovorin 7
5-FU + oxaliplatin 1
5-FU + oxaliplatin + folinic acid 1
Capecitabine 124
Capecitabine + oxaliplatin 3
Cetuximab 2
CORE trial 6
De Gramont regime 3
DESCARTES 11
Mitomycin 1
Palliative chemotherapy 1
SOCRATES 22
Tomudex 1
Tomudex + oxaliplatin 1
XELOX trial 15
Total 463
5-FU, 5-ﬂuorouracil; BOSSET, regime with different doses of
5-FU; CORE trial, Phase II study – Chemoradiation with
Oxaliplatin in Rectal Cancer; de Gramont regime, regime using
ﬂuorouracil and folinic acid; DESCARTES, regime using irino-
tecan in the chemoradiation; SOCRATES, Phase II study –
oxaliplatin, capecitabine and radiotherapy; XELOX, capecita-
bine and oxaliplatin.
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12.0 g/dl, patients with Hb < 12 g/dl showed less
response to neoadjuvant chemoradiation, if regression
of T stage was considered as a response (P = 0.03).
Patients with Hb ≥ 12 g/dl showed a strong associa-
tion with a pathological complete response in univariate
analysis (P = 0.02); however, this association was lost in
multivariate analysis.
Hb vs long-term prognosis
Over a median follow-up period of 24 (1–95) months,
the crude local recurrence rate was 20.3% and the
3-year actuarial local recurrence was 8%. The statistical
model used to determine risk factors of local recurrence
showed that pretreatment Hb < 12g/dl (hazard
ratio > 1; Fig. 1 and Table 3), higher pretreatment
T stage, shorter distance from the anal verge and high
baseline CEA value increase the risk of local recurrence.
The inﬂuence of Hb < 12 g/dl on local recurrence was
not statistically signiﬁcant (P = 0.08). We did not ﬁnd a
relationship between Hb level and distant metastasis or
overall survival.
Discussion
Pretreatment anaemia has shown signiﬁcant prognostic
value in solid cancers, including tumours of the head
and neck [13], breast [14], oesophagus [15], stomach
[16], uterine cervix [17] and bladder [18]. Intraluminal
bleeding from a friable endoluminal tumour surface can
result in substantial blood loss and therefore the degree
of anaemia is commonly severe in gastrointestinal
tumours compared with anaemia as a paraneoplastic
phenomenon in other malignancies. About 30% of
patients with rectal cancer present with anaemia [19].
The presence of pretreatment anaemia in rectal cancer
patients is associated with a worse tumour response [4],
locoregional control [3], disease-free survival [5] and
overall survival [2]. Our results support the association
of pretreatment Hb with tumour response and locore-
gional control. Moreover, our analysis showed that
non-anaemic patients were more likely to achieve a
pathological complete response in univariate analysis.
Morphometric characteristics of tumour in resected
specimens have been shown to be independent prog-
nostic markers in early-stage cancer of the uterine cer-
vix [20] and predictors of positive lymph nodes in
colorectal cancers [21]. In rectal cancer, pretreatment
tumour size has been shown to inﬂuence the outcome
of laparoscopic surgery [22]. Therefore, pretreatment
tumour length may have a prognostic role. Our study
demonstrates that the pretreatment Hb level might
reﬂect endoluminal tumour length and pretreatment
clinical T stage. Patients with larger tumours had
signiﬁcantly lower Hb levels.
Table 3 Final parameters with signiﬁcant inﬂuence on local
recurrence in 3 years.
Risk factors Hazard ratio P-value
Distance from anal verge (cm) 0.86 0.03
CEA value 1.00 0.01
Operation type 2.07 0.00
Distant metastasis 6.45 0.00
Cut-off Hb levels (12 g/dl) 1.78 0.08
Tumour length (cm) 1.17 0.01
CEA, carcinoembryonic antigen.
Note that patients with a haemoglobin (Hb) of < 12 g/dl are
at risk of developing local recurrence (hazard ratio = 1.78) but
this was not statistically signiﬁcant (P = 0.08).
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Figure 1 Kaplan–Meier curves showing a statistically signiﬁ-
cant difference in the frequency (a) and risk (b) of local recur-
rence between patients with a baseline haemoglobin (Hb) of
less (blue line) or more (green line) than 12 g/dl.
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tumour behaviour and poor prognosis through exacer-
bating tumour hypoxia [23]. There are several biologi-
cal factors that can explain how anaemia can lead to a
poor outcome. Evidence from studies on cancer of the
head and neck [24] and the uterine cervix [25] and on
soft tissue sarcomas [26] clearly demonstrate the
adverse prognostic impact of tumour hypoxia. Within
the tumour bed, structural and functional abnormalities
result in haphazard architecture, hindering oxygen
diffusion from vessels to individual cells and causing
hypoxia. Low oxygen tension within cancer cells insti-
gates biological behaviours that lead to a more aggres-
sive phenotype and the induction of angiogenesis. High
levels of circulating angiogenic factors have also been
reported in patients with anaemia [27]. Furthermore,
the effectiveness of radiotherapy is dependent on the
generation of free oxygen radicals that induce DNA and
membrane damage within cancer cells [28]. Lack of
oxygen within tissue hinders free-radical generation,
hence creating resistance to treatment. Tumour hypoxia
also seems to diminish the efﬁcacy of certain chemo-
and immunotherapeutics that are dependent on normal
local oxygen levels.
Correction of pretreatment anaemia provides symp-
tomatic relief but without any effect on tumour behav-
iour [29]. Homologous blood transfusion has been
shown to increase infective complications as a result of
immunosuppressive effects, especially if given periopera-
tively [30]. Erythropoiesis-stimulating agents (ESA)
have been shown to counteract the effects of cancer-
induced anaemia, but a recent meta-analysis of random-
ized controlled trials did not show any signiﬁcant effect
on survival and disease progression. There is also an
added risk of thromboembolic complications [31].
However, treatment with ESA has not been tried in
rectal cancer [32]. Hence, anaemia may be an inherent
feature of tumours with aggressive potential, and the
pretreatment Hb level may be simply a marker of such
behaviour.
One weakness of the study was the accuracy of the
measurement of tumour length. Preoperatively this is
observer dependent and therefore repeatability analysis
of this parameter should be included in future studies.
Another limitation of this study was that not all
surgeons were performing TME in the 1990s and
therefore the quality of surgery was variable.
We propose risk categorization [33] of patients pre-
senting with rectal cancer as a possible way of individu-
alizing management. Anaemia should be considered as a
potential risk factor associated with poor tumour
morphology, more aggressive behaviour and worse
long-term prognosis. Measurement of Hb is simple and
cheap and may distinguish rectal cancer subtypes with
distinct clinical courses. The use of Hb level may
improve decision-making, and perhaps combinations of
factors such as Hb level, tumour length and T stage
may, in future, allow deﬁnition of distinct subgroups
with differing clinical biology.
In conclusion, we have shown that the pretreatment
Hb level provides information on the nature of the
rectal cancer and its potential behaviour in resistance
to treatment and the chance of local recurrence. Our
analysis revealed Hb to be a clinically applicable bio-
marker, which may be useful in large prospective trials
to assess risk-adapted therapies. Absolute and cut-off
values of Hb could easily and reliably be used between
different laboratories to classify high- and low-risk
groups.
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